Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J, Xie Y, Guo J, Li X, Wang J, Jiang H, Peng Z, Wang J, Wang S, Li Q, Ye L, Zhong Y, Zhang Q, Liu X, Lonard DM, Wang J, O'Malley BW, Liu Z.
Liu J, et al. Among authors: li x, li q.
Nat Commun. 2021 Feb 15;12(1):1022. doi: 10.1038/s41467-021-21386-y.
Nat Commun. 2021.
PMID: 33589584
Free PMC article.